Eyestem Research has raised $10 million in an oversubscribed round to complete the ongoing Phase 2 clinical trial of its retinal cell therapy, Eyecyte-RPE™, in India and prepare for a US FDA IND filing. The therapy targets geographic atrophy in dry AMD, with Phase 1 showing early vision improvement. Funding will aid clinical progress and global expansion.